These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 6451281)

  • 1. Uptake and decomposition of chlorozotocin in L5178Y lymphoblasts in vitro.
    Lam HY; Talgoy MM; Goldenberg GJ
    Cancer Res; 1980 Nov; 40(11):3950-5. PubMed ID: 6451281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of uptake of nitrosoureas by L5178Y lymphoblasts in vitro.
    Begleiter A; Lam HP; Goldenberg GJ
    Cancer Res; 1977 Apr; 37(4):1022-7. PubMed ID: 557367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for carrier-mediated transport of melphalan by L5178Y lymphoblasts in vitro.
    Goldenberg GJ; Lee M; Lam HY; Begleiter A
    Cancer Res; 1977 Mar; 37(3):755-60. PubMed ID: 837375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of adriamycin uptake in chick embryo heart and liver cells an murine L5178Y lymphoblasts in vitro: role of drug uptake in cardiotoxicity.
    Johnson BA; Cheang MS; Goldenberg GJ
    Cancer Res; 1986 Jan; 46(1):218-23. PubMed ID: 3940192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of efflux of melphalan from L5178Y lymphoblasts in vitro.
    Begleiter A; Grover J; Goldenberg GJ
    Cancer Res; 1982 Mar; 42(3):987-91. PubMed ID: 7059994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological and biochemical properties of 1-(2-chloroethyl)-3-(beta-D-glucopyranosyl)-1-nitrosourea (NSC D 254157), a nitrosourea with reduced bone marrow toxicity.
    Fox PA; Panasci LC; Schein PS
    Cancer Res; 1977 Mar; 37(3):783-7. PubMed ID: 138478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic disposition of chlorozotocin in mice.
    Mhatre RM; Green D; Panasci LC; Woolley PV; Schein PS
    Cancer Treat Rep; 1978 Aug; 62(8):1145-51. PubMed ID: 150943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uptake and decomposition of chlorambucil by L5178Y lymphoblasts in vitro.
    Begleiter A; Goldenberg GJ
    Biochem Pharmacol; 1983 Feb; 32(3):535-9. PubMed ID: 6847702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the biological and biochemical properties of 1-(4-amino-2-methylpyrimidin-5-yl)methyl-3-(2-chloroethyl)-3-nitrosourea and 2-[3-(2-chloroethyl)-3-nitrosoureido]-D-glucopyranose.
    Nagourney RA; Fox P; Schein PS
    Cancer Res; 1978 Jan; 38(1):65-8. PubMed ID: 145314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transport of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea in the human glioma cell line SK-MG-1 is mediated by an epinephrine-sensitive carrier system.
    Noë AJ; Malapetsa A; Panasci LC
    Mol Pharmacol; 1993 Jul; 44(1):204-9. PubMed ID: 8341272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for active transport of melphalan by two amino acid carriers in L5178Y lymphoblasts in vitro.
    Begleiter A; Lam HY; Grover J; Froese E; Goldenberg GJ
    Cancer Res; 1979 Feb; 39(2 Pt 1):353-9. PubMed ID: 570091
    [No Abstract]   [Full Text] [Related]  

  • 12. Mechanism of cyclophosphamide transport by L5178Y lymphoblasts in vitro.
    Goldenberg GJ; Land HB; Cormack DV
    Cancer Res; 1974 Dec; 34(12):3274-82. PubMed ID: 4529665
    [No Abstract]   [Full Text] [Related]  

  • 13. Low-molecular weight inhibitory factor released in vitro by murine L5178Y leukemic cells.
    Chmurzyńska W; Grzelakowska-Sztabert B
    Neoplasma; 1987; 34(5):513-21. PubMed ID: 2447509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of calcium and glucose uptake by murine leukemia L5178Y cells treated with antiserum.
    Woodcock-Mitchell J; Yang TJ
    J Cell Physiol; 1980 Dec; 105(3):423-9. PubMed ID: 7462334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uptake and metabolism of hexamethylmelamine and pentamethylmelamine by L5178Y lymphoblasts in vitro.
    Begleiter A; Grover J; Goldenberg GJ
    Cancer Res; 1980 Dec; 40(12):4489-94. PubMed ID: 6777039
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase I trial of chlorozotocin: attempted amelioration of myelotoxicity by glucose administration.
    Panasci L; Comis R; Ginsberg S; Kohn L; Fitzpatrick A; Rubert M; Scalzo T
    Cancer Treat Rep; 1981; 65(7-8):647-50. PubMed ID: 6454483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carcinogenic activity in Sprague-Dawley rats of 2-[3-(2-chloroethyl)-3-nitrosoureido]-D-gluco-pyranose (chlorozotocin).
    Habs M; Eisenbrand G; Schmähl D
    Cancer Lett; 1979 Dec; 8(2):133-7. PubMed ID: 162366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular and molecular mechanisms of the bone marrow sparing effects of the glucose chloroethylnitrosourea chlorozotocin.
    Byrne P; Tew K; Jemionek J; MacVittie T; Erickson L; Schein P
    Blood; 1984 Apr; 63(4):759-67. PubMed ID: 6322885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chlorambucil pharmacokinetics and DNA binding in chronic lymphocytic leukemia lymphocytes.
    Bank BB; Kanganis D; Liebes LF; Silber R
    Cancer Res; 1989 Feb; 49(3):554-9. PubMed ID: 2910477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the transport of chlorozotocin and CCNU in L1210 leukemia and murine bone marrow cells in vitro.
    Lazarus P; Germina JS; Dufour M; Palmer G; Wallace D; Panasci LC
    Cancer Chemother Pharmacol; 1983; 11(3):159-61. PubMed ID: 6227421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.